WAT · Earnings call · 2026Q2T · Full report
Regulatory Approval Milestones
WATERS CORP /DE/ · 2026-08-04 · Importance 53 · Surprise 60 · In source text
Waters received U.S. FDA 510(k) clearance for the BACTEC FXI next-generation blood-culture system. The clearance enables U.S. commercialization, while placements had already begun in Japan and Europe. Management identified approximately 12,000 installed BACTEC systems past due for replacement, including roughly 4,500 in the United States, supporting a multiyear replacement opportunity.
Key facts
- BACTEC FXI received FDA 510(k) clearance enabling U.S. commercialization
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | BACTEC FXI received FDA 510(k) clearance enabling U.S. commercialization |